Klin Farmakol Farm. 2026;40(3):186-190 | DOI: 10.36290/far.2026.028

Cefiderocol in the treatment of infectious complications caused by a multidrug-resistant strain of Acinetobacter baumannii in a patient with severe burns

David Janák1, Bohumil Bakalář1, Mousa Awies1, Cecílie Stonová1, Marta Fridrichová2, Břetislav Lipový1, Robert Zajíček1
1 Klinika popáleninové medicíny Fakultní nemocnice Královské Vinohrady a 3. lékařské fakulty Univerzity Karlovy, Praha
2 Centrální laboratoře Fakultní nemocnice Královské Vinohrady - úsek mikrobiologie, Praha

Infections caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) pose a serious problem, particularly in critically ill burn patients with immunological dysfunction who require long-term intensive care. The high rate of MDR-AB resistance limits treatment options and is associated with a poor prognosis. The isolated MDR-AB strain in our case showed multidrug resistance with limited options for effective antimicrobial treatment. Based on microbiological testing, targeted treatment with cefiderocol was indicated. This case report supports the successful use of cefiderocol as an effective and safe therapeutic alternative for severe infections caused by MDR-AB in burn patients and highlights its potential role in treating infections for which established antibiotics are ineffective.

Keywords: cefiderocol, infection, dermal substitute.

Received: May 11, 2026; Revised: July 29, 2026; Accepted: July 29, 2026; Published: October 14, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janák D, Bakalář B, Awies M, Stonová C, Fridrichová M, Lipový B, Zajíček R. Cefiderocol in the treatment of infectious complications caused by a multidrug-resistant strain of Acinetobacter baumannii in a patient with severe burns. Klin Farmakol Farm. 2026;40(3):186-190. doi: 10.36290/far.2026.028.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Jeschke MG, Pinto R, Kraft R, et al. Morbidity and survival probability in burn patients in modern burn care. Crit Care Med. 2015;43(4):808-815. Go to original source...
    2. Ruegsegger L, Xiao J, Naziripour A, et al. Multidrug-Resistant Gram-Negative Bacteria in Burn Patients. Antimicrob Agents Chemother. 2022;66(9):e0068822. Go to original source...
    3. Kabanangi F, Joachim A, Nkuwi EJ, et al. High Level of Multidrug-Resistant Gram-Negative Pathogens Causing Burn Wound Infections in Hospitalized Children in Dar es Salaam, Tanzania. Int J Microbiol. 2021;2021:6644185. Go to original source...
    4. Vickers ML, Dulhunty JM, Ballard E, et al. Risk factors for multidrug-resistant Gram-negative infection in burn patients. ANZ J Surg. 2018;88(5):480-485. Go to original source...
    5. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. Go to original source...
    6. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. London: Review on Antimicrobial Resistance; [Internet]. 2016 [cited 2024 Nov 14]. Available from: https://amr-review.org.
    7. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; [Internet]. 2017 [cited 2024 Nov 14]. Available from: www.who.int.
    8. Miller WR, Arias CA. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat Rev Microbiol. 2024;22(10):598-616. Go to original source... Go to PubMed...
    9. Church D, Elsayed S, Reid O, et al. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403-434. Go to original source... Go to PubMed...
    10. Lachiewicz AM, Hauck CG, Weber DJ, et al. Bacterial Infections After Burn Injuries: Impact of Multidrug Resistance. Clin Infect Dis. 2017;65(12):2130-2136. Go to original source...
    11. Wang H, Palasik BN. Combating antimicrobial resistance with cefiderocol for complicated infections involving the urinary tract. Ther Adv Urol. 2022;14:1-9. Go to original source... Go to PubMed...
    12. Bianco G, Boattini M, Cricca M, et al. Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol. Clin Microbiol Infect. 2024;46(12):14132-14153. Go to original source... Go to PubMed...
    13. Wang L, Zhu J, Chen L, Du H. Cefiderocol: Clinical Application and Emergence of Resistance. Drug Resistance Updat. 2024;72:101034. Go to original source... Go to PubMed...
    14. Bassetti M, Garau J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother. 2021;76(Suppl 4):23-37. Go to original source...
    15. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226-240. Go to original source...
    16. Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: Systematic Review of Mechanisms of Resistance, Pharmacokinetics and Pharmacodynamics, and Clinical Efficacy. Antibiotics (Basel). 2022;11(6):783. Go to original source... Go to PubMed...
    17. Abdul-Mutakabbir JC, Alosaimy S, Morrisette T, et al. Cefiderocol: A novel Siderophore cephalosporin against multi­drug-resistant gram-negative pathogens. Pharmacotherapy. 2020;40(12):1228-1247. Go to original source... Go to PubMed...
    18. Kaki R, Taj A, Bagaaifar S. The Use of Cefiderocol in Gram-Negative Bacterial Infections at International Medical Center, Jeddah, Saudi Arabia. Antibiotics (Basel). 2024;13(11):1043. Go to original source... Go to PubMed...
    19. Vardakas KZ, Rafailidis PI, Konstantelias AA, et al. Predictors of mortality in patients with infections due to multi-drug resistant Gram-negative bacteria: The study, the patient, the bug or the drug? J Infect. 2013;66(5):401-414. Go to original source...
    20. Norbury W, Herndon DN, Tanksley J, et al. Infection in Burns. Surg Infect (Larchmt). 2016;17(2):250-255. Go to original source... Go to PubMed...
    21. Theuretzbacher U, Outterson K, Engel A, et al. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18(5):275-285. Go to original source... Go to PubMed...
    22. Vinaik R, Barayan D, Shahrokhi S, et al. Management and prevention of drug resistant infections in burn patients. Expert Rev Anti Infect Ther. 2019;17(8):607-619. Go to original source...
    23. van Langeveld I, Gagnon RC, Conrad PF, et al. Multiple-Drug Resistance in Burn Patients: A Retrospective Study on the Impact of Antibiotic Resistance on Survival and Length of Stay. J Burn Care Res. 2017;38(2):99-105. Go to original source... Go to PubMed...
    24. Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. Published online August 7, 2024.
    25. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521-547. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.